GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

Mostrar otras versiones (1)

There is no consensus as to the management of untreated poor prognosis or relapsed/refractory germ cell tumours. We have studied an intensive cisplatin-based regimen that incorporates high-dose methotrexate (HD MTX) and actinomycin-D and etoposide every 14 days (GAMEC). Sixty-two patients were enrol...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamash, J, Powles, T, Ansell, W, Stebbing, J, Mutsvangwa, K, Wilson, P, Asterling, S, Liu, S, Wyatt, P, Joel, S P, Oliver, R T D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360316/
https://www.ncbi.nlm.nih.gov/pubmed/17609665
http://dx.doi.org/10.1038/sj.bjc.6603865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360316/
https://www.ncbi.nlm.nih.gov/pubmed/17609665
http://dx.doi.org/10.1038/sj.bjc.6603865

Ejemplares similares